Detalles de la búsqueda
1.
HER2 mutation as an emerging target in advanced breast cancer.
Cancer Sci
; 2024 May 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-38715247
2.
The Molecular Tumor Board of the Regina Elena National Cancer Institute: from accrual to treatment in real-world.
J Transl Med
; 21(1): 725, 2023 10 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-37845764
3.
Biomarkers of Response and Resistance to CDK4/6 Inhibitors in Breast Cancer: Hints from Liquid Biopsy and microRNA Exploration.
Int J Mol Sci
; 23(23)2022 Nov 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-36498861
4.
Burnout of health care providers during the COVID-19 pandemic: Focus on Medical Oncologists.
Int J Med Sci
; 18(10): 2235-2238, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33859532
5.
Second-line Eribulin in Triple Negative Metastatic Breast Cancer patients. Multicentre Retrospective Study: The TETRIS Trial.
Int J Med Sci
; 18(10): 2245-2250, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33859534
6.
COVID-19 risk in breast cancer patients receiving CDK4/6 inhibitors: literature data and a monocentric experience.
Breast J
; 27(4): 359-362, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33677841
7.
Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence.
J Cell Physiol
; 235(11): 7900-7910, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31943171
8.
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting.
Int J Cancer
; 146(7): 1917-1929, 2020 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31330065
9.
Cancer patients and coronavirus disease 2019: evidence in context.
J Transl Med
; 18(1): 315, 2020 08 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-32799883
10.
Neoadjuvant Endocrine Therapy in Breast Cancer: Current Knowledge and Future Perspectives.
Int J Mol Sci
; 21(10)2020 May 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-32429381
11.
TRF2 as novel marker of tumor response to taxane-based therapy: from mechanistic insight to clinical implication.
J Exp Clin Cancer Res
; 43(1): 75, 2024 Mar 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-38459559
12.
Sexual dysfunctions in breast cancer patients: evidence in context.
Sex Med Rev
; 11(3): 179-195, 2023 06 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-37076125
13.
DARPP-32 and t-DARPP in the development of resistance to anti-HER2 agents. Pre-clinical evidence from the STEP study.
Neoplasia
; 45: 100937, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37769528
14.
Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study.
Front Oncol
; 13: 1152123, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37260975
15.
KEAP1-Mutant NSCLC: The Catastrophic Failure of a Cell-Protecting Hub.
J Thorac Oncol
; 17(6): 751-757, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35351670
16.
The Role of the CDK4/6 Inhibitor Ribociclib in Locally Advanced and Oligometastatic Hormone Receptor Positive, Her2 Negative, Advanced Breast Cancer: Case Series and Review of the Literature.
Front Oncol
; 12: 797157, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35223478
17.
The Impact of the Hippo Pathway and Cell Metabolism on Pathological Complete Response in Locally Advanced Her2+ Breast Cancer: The TRISKELE Multicenter Prospective Study.
Cancers (Basel)
; 14(19)2022 Oct 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36230758
18.
Prognostic Relevance of Neutrophil to Lymphocyte Ratio (NLR) in Luminal Breast Cancer: A Retrospective Analysis in the Neoadjuvant Setting.
Cells
; 10(7)2021 07 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34359855
19.
Palliative- and non-palliative indications for glucocorticoids use in course of immune-checkpoint inhibition. Current evidence and future perspectives.
Crit Rev Oncol Hematol
; 157: 103176, 2021 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-33276183
20.
CDK4/6 Inhibitor Treatments in Patients with Hormone Receptor Positive, Her2 Negative Advanced Breast Cancer: Potential Molecular Mechanisms, Clinical Implications and Future Perspectives.
Cancers (Basel)
; 13(2)2021 Jan 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-33477469